Ko Michelle Y, Williamson Eric
Medicine, University of California Los Angeles David Geffen School of Medicine, Los Angeles, USA.
Neurology, University of California Los Angeles David Geffen School of Medicine, Los Angeles, USA.
Cureus. 2025 May 21;17(5):e84587. doi: 10.7759/cureus.84587. eCollection 2025 May.
The association between the discontinuation of therapies and "rebound" multiple sclerosis (MS) activity has been frequently reported, yet is incompletely understood. We report an older male with previously well-controlled MS who was taken off his decade-long fingolimod treatment due to disseminated zoster infection, who subsequently experienced two severe MS exacerbations within six weeks. Though clinicians should consider possible confounding influences from infections such as varicella-zoster virus (VZV) and COVID-19, this case raised the most concern for suspicion of early fingolimod-associated rebound.
治疗中断与“反弹”型多发性硬化症（MS）活动之间的关联已被频繁报道，但尚未完全了解。我们报告了一名老年男性，他之前的MS病情控制良好，因播散性带状疱疹感染而停用了长达十年的芬戈莫德治疗，随后在六周内经历了两次严重的MS病情加重。尽管临床医生应考虑水痘-带状疱疹病毒（VZV）和COVID-19等感染可能产生的混杂影响，但该病例最令人担忧的是怀疑早期芬戈莫德相关的反弹。
